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Introduction
Breast cancer is a leading cause of death in women, due primarily
to ineffective treatment of metastasis. Metastasis is a multi-step
process that involves tumour cell escape from the primary tumour,
migration through the body, adhesion and extravasation at the
secondary site, initiation of micrometastatic growth and mainte-
nance of growth into clinically detectable macrometastases [1].
Given the onerous nature of this process, it is not surprising that
metastasis is highly inefficient, with the main rate-limiting steps
being initiation and maintenance of growth at secondary sites
[1–3]. Taken together with the heterogeneous nature of solid
tumours, this metastatic inefficiency suggests that only a small
subset of cells can successfully navigate the metastatic cascade
and eventually re-initiate tumour growth to form metastases.
However, the ability to specifically identify and target this deadly
subset of cells has remained elusive.
In light of several pivotal studies demonstrating the existence
of ‘stem-like’ cells or cancer stem cells (CSCs) in leukaemia [4, 5]
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Abstract
Cancer stem cells (CSCs) have recently been identified in leukaemia and solid tumours; however, the role of CSCs in metastasis remains
poorly understood. This dearth of knowledge about CSCs and metastasis is due largely to technical challenges associated with the use
of primary human cancer cells in pre-clinical models of metastasis. Therefore, the objective of this study was to develop suitable pre-
clinical model systems for studying stem-like cells in breast cancer metastasis, and to test the hypothesis that stem-like cells play a key
role in metastatic behaviour. We assessed four different human breast cancer cell lines (MDA-MB-435, MDA-MB-231, MDA-MB-468,
MCF-7) for expression of prospective CSC markers CD44/CD24 and CD133, and for functional activity of aldehyde dehydrogenase
(ALDH), an enzyme involved in stem cell self-protection. We then used fluorescence-activated cell sorting and functional assays to char-
acterize differences in malignant/metastatic behaviour in vitro (proliferation, colony-forming ability, adhesion, migration, invasion) and
in vivo (tumorigenicity and metastasis). Sub-populations of cells demonstrating stem-cell-like characteristics (high expression of CSC
markers and/or high ALDH) were identified in all cell lines except MCF-7. When isolated and compared to ALDHlowCD44low/– cells,
ALDHhiCD44CD24 (MDA-MB-231) and ALDHhiCD44CD133 (MDA-MB-468) cells demonstrated increased growth (P  0.05),
colony formation (P  0.05), adhesion (P  0.001), migration (P  0.001) and invasion (P  0.001). Furthermore, following tail vein
or mammary fat pad injection of NOD/SCID/IL2 receptor null mice, ALDHhiCD44CD24 and ALDHhiCD44CD133 cells showed
enhanced tumorigenicity and metastasis relative to ALDHlowCD44low/– cells (P  0.05). These novel results suggest that stem-like
ALDHhiCD44CD24 and ALDHhiCD44CD133 cells may be important mediators of breast cancer metastasis.
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and several types of solid cancer [6–11], we and others have
speculated that CSCs may represent the subset of tumour cells
responsible for metastatic disease [12, 13]. However, while sev-
eral studies have demonstrated the ability of CSCs to initiate and
maintain a primary tumour [6–11], the functional contribution of
CSCs to metastatic behaviour remains poorly understood.
In breast cancer, stem-like cells have been prospectively iso-
lated from primary tumours and pleural effusions based on a
CD44CD24 phenotype [6]. Subsequent experimental studies
have also isolated CD44CD24 breast cancer cells and demon-
strated increased in vitro expression of stem cell markers and
enhanced capacity for mammosphere formation, invasion and
resistance to radiation [14–16]. Furthermore, clinical studies indi-
cate that CD44CD24 tumour-initiating cells express an invasive
gene signature and may be associated with distant metastases
[17–19]. Additional putative CSC phenotypes have also been iden-
tified in other solid cancers, including CD133 (brain, colon, pan-
creatic cancer) [8, 9, 11] and CD44CD133 (prostate cancer)
[7]. However, because of the heterogeneous nature of solid can-
cers, the reliability of using cell surface markers as the sole way to
isolate CSCs remains controversial [20–23]. Furthermore, human
stem cell sources (including tumours) may contain alternate
stem/progenitor cell lineages not efficiently isolated using variably
expressed cell surface markers.
A complementary strategy for identifying stem-like tumour
cells involves measurement of aldehyde dehydrogenase (ALDH)
activity, an enzyme involved in intracellular retinoic acid production
[24]. Retinoic acid signalling is linked to cellular differentiation
during development and plays a role in stem cell self-protection
throughout an organism’s lifespan [25]. We and others have pre-
viously used this isolation strategy alone or in combination with
cell surface markers (i.e. CD133) to successfully isolate normal
human haematopoietic progenitor cells [26–28], and ALDH 
activity has also been used to identify stem-like subsets in human
haematopoietic cancers [29–31]. A recent study by Ginestier et al.
(2007) elegantly demonstrated that expression of ALDH1 in breast
tumours was a predictor of poor clinical outcome, and that high
ALDH activity selects for both normal and tumorigenic human
mammary epithelial cells with stem/progenitor properties [32].
Therefore, the use of ALDH activity as a purification strategy allows
non-toxic and efficient isolation of human stem-like cells based on
a developmentally conserved stem/progenitor cell function.
Although there is growing evidence supporting the existence of
CSCs in solid tumours, what remains less clear is the impact 
of CSCs on metastatic behaviour. We believe that the dearth of
knowledge about CSCs and metastasis is due largely to technical
challenges associated with the use of primary human cancer cells
in pre-clinical models of metastasis: even in nonobese diabetic/
severe combined immune-deficient (NOD/SCID) mice, it is very
difficult to grow primary cells as xenograft tumours, much less as
metastases. Therefore, workable alternative model systems must
be developed in order to address this need. It has long been
observed by tumour biologists that even with cancer cell lines,
large numbers of cells need to be injected to form a tumour and/or
metastasize in experimental animals [1, 2, 33]. This suggests that
not all cells within a cell line population are equal, and only a small
subset of cells is capable of tumour initiation and progression to
metastasis. Indeed, studies have shown that commonly used cell
lines contain subpopulations of cells with stem-like properties
[14–16]. Thus, the purification of stem-like cells from cell lines
may provide a valuable model system for starting to investigate
the role of such cells in breast cancer metastasis.
In the current study, we assessed four commonly used human
breast cancer cell lines (including highly metastatic MDA-MB-435
[see note in section ‘Materials and Methods’], moderately
metastatic MDA-MB-231, weakly metastatic MDA-MB-468 and
non-metastatic MCF-7) for expression of the prospective CSC
markers CD44/CD24 and CD133, and for functional activity of
ALDH. We then used fluorescence-activated cell sorting (FACS)
and standard functional assays to characterize differences in
malignant/metastatic behaviour between cell populations, includ-
ing cell growth, adhesion, migration, and invasion in vitro, and
tumorigenicity and metastasis in vivo. The novel findings pre-
sented here suggest that high ALDH activity and CSC marker
expression select for stem-like breast cancer cells with enhanced
malignant and metastatic properties, and that
ALDHhiCD44CD24 and ALDHhiCD44CD133 stem-like cells
may be important contributors to breast cancer metastasis.
Material and methods
Cell culture
MDA-MB-231 and MCF-7 cells were obtained from ATCC (Manassas, VA,
USA). MDA-MB-435 and MDA-MB-468 cells were obtained from Dr. Janet
Price (M.D. Anderson Cancer Center, Houston, TX, USA [34]). MDA-MB-
435 and MDA-MB-468 cells were grown in MEM  10% foetal bovine
serum (FBS), MCF-7 cells were grown in DMEM  10% FBS and MDA-
MB-231 cells were grown DMEM:F12  10% FBS. Media were obtained
from Invitrogen (Carlsbad, CA, USA). FBS was obtained from Sigma (St.
Louis, MO, USA). It should be noted that the MDA-MB-435 cell line was
originally isolated from the pleural effusion of a woman with metastatic
breast adenocarcinoma [34]. Recently, a debate has arisen over the origins
of this cell line, whether it was derived from the M14 melanoma cell or is
in fact a true breast cancer cell line [35, 36]. Whether melanoma or breast
in origin, the MDA-MB-435 cell line does represent a highly metastatic cell
line, and thus provides an opportunity to relate functional metastatic ability
to expression of CSC-related markers.
Cell surface marker analysis
MDA-MB-435, MDA-MB-231, MDA-MB-468 and MCF-7 cells (1  105) were
incubated with fluorescently conjugated antibodies, including anti-CD24
(clone ML5; BD Biosciences Canada, Mississauga, ON, Canada) or anti-
CD133 (clone AC133; Miltenyi Biotec, Auburn, CA, USA) conjugated to phy-
coerytherin (PE); and anti-CD44 (clone IM7; BD Biosciences) conjugated to
fluorescein isothiocyanate (FITC). For supplemental studies, MDA-MB-231
and MDA-MB-468 cells were also incubated with anti-CXCR4 (clone 12G5;
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R&D Systems, Minneapolis, MN, USA) conjugated to PE. Fluorescently
conjugated immunoglobulin G (IgG) isotype controls (BD Biosciences)
were used as negative controls. Cells were analysed using a Beckman Coulter
EPICS XL-MCL flow cytometer (Beckman Coulter, Fullerton, CA, USA).
Analysis of ALDH activity
To assess ALDH activity of the different cell lines, the ALDEFLUOR® assay
kit (StemCell Technologies, Vancouver, BC, Canada) was used. The basis
for this assay is that uncharged ALDH substrate (BODIPY-aminoacetalde-
hyde [BAAA]) is taken up by living cells via passive diffusion. Once inside
the cell, BAAA is converted into negatively charged BODIPY-aminoacetate
(BAA) by intracellular ALDH. BAA is then retained inside the cell, causing
the cell to become highly fluorescent. Only cells with an intact cell mem-
brane can retain BAA, so only viable cells can be identified [24]. The
ALDEFLUOR® assay was performed essentially as described previously
[26–28]. Briefly, MDA-MB-435, MDA-MB-231, MDA-MB-468 and MCF-7
cells were harvested, placed in ALDEFLUOR® assay buffer (2  106/ml)
and incubated with the ALDEFLUOR® substrate for 45 min. at 37C to allow
substrate conversion. As a negative control for all experiments, an aliquot
of ALDEFLUOR®-stained cells was immediately quenched with 1.5-mM
diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor. Cells were
analysed using the green fluorescence channel (FL1) on a Beckman Coulter
EPICS XL-MCL flow cytometer. Human umbilical cord blood (discard prod-
uct) was labelled and assayed for ALDH activity as described previously
[27] in order to optimize and validate the flow cytometry protocol.
FACS isolation of cells
Based on cell surface marker phenotype and ALDH activity, MDA-MB-468
and MDA-MB-231 cell lines were chosen for further cell isolation by
FACS and functional analysis. Cells were concurrently labelled with 
7-Amino-actinomycin (7-AAD), fluorescent antibodies (CD44-APC 
CD24-PE [MDA-MB-231] or CD44-APC  CD133-PE [MDA-MB-468])
and the ALDEFLUORTM assay kit as described above. Cell subsets were
isolated using a four-colour analysis protocol on a FACS Vantage/Diva
cell sorter (BD Biosciences), including ALDHhiCD44CD24 and
ALDHlowCD44low/CD24 subsets (from MDA-MB-231 cells) and
ALDHhiCD44CD133 and ALDHlowCD44low/CD133 subsets (from
MDA-MB-468 cells). For both cell lines, ALDH activity was used as the
primary sort criteria (top ~20% 	 ALDHhi; bottom ~20% 	 ALDHlow)
and CD44CD24 (MDA-MB-231 cells) or CD44CD133 (MDA-MB-
468 cells) phenotype as the secondary sort criteria (top ~10% gated on
ALDHhi; bottom ~10% gated on ALDHlow). Cell viability was assessed by
7-AAD staining during cell sorting, and confirmed by trypan blue exclu-
sion after sorting. Following FACS isolation, cells were used immediately
for functional in vitro and in vivo assays.
Cell proliferation assays
Sorted cell populations (ALDHhiCD44CD24 and ALDHlowCD44low/CD24
from MDA-MB-231 cells; ALDHhiCD44CD133 and ALDHlowCD44low/CD133
from MDA-MB-468 cells) were plated at a density of 5.0  104 cells/60
mm plate (n 	 3 for each time-point) and maintained in regular growth
media. Every 48 hrs for 14 days, triplicate cultures were trypsinized and
counted by hemocytometer. Doubling time of each cell population was esti-
mated during the exponential growth phase according to Td 	 0.693t /ln
(Nt /N0), where t is time (in hours), Nt is the cell number at time t and N0 is
the cell number at initial time. Lag time was taken as the time for each pop-
ulation to reach the exponential growth phase.
Colony forming assays
In preparation for the assay, 60 mm dishes were coated with 1% agarose
(Bioshop; Burlington, ON, Canada) in normal growth media and allowed to
set for 1 hr. Cell suspensions (1.0  104 cells/60 mm plate) for each sorted
population (ALDHhiCD44CD24 and ALDHlowCD44low/CD24 from
MDA-MB-231 cell line; ALDHhiCD44CD133 and ALDHlowCD44low/CD133
from MDA-MB-468 cell line) were prepared using 0.6% agarose in normal
growth media and plated on top of the 1% agarose base layer (n 	 4 for
each time-point). Normal growth media were added on top of the cell layer
and changed every 3–4 days for 4 weeks, at which time media were
removed and plates were fixed in 10% neutral-buffered formalin (EM
Sciences, Gladstone, NJ, USA). Five fields of view (100) were counted
for each dish, and mean number of colonies/field and mean colony diam-
eter was calculated.
Cell adhesion assays
Cells were plated onto sterile 96-well non-tissue culture plates (Titertek, Flow
Laboratories, Inc.; McLean, VA, USA) treated with either 10 
g/ml of human
fibronectin (Sigma) (MDA-MB-231 cells), 5 
g/ml of human vitronectin
(Sigma) (MDA-MB-468 cells), or phosphate-buffered saline (PBS) (negative
control), using 1104 cells/well (n 	 3) for each sorted cell population
(ALDHhiCD44CD24 and ALDHlowCD44low/CD24 from MDA-MB-231 cell
line; ALDHhiCD44CD133 and ALDHlowCD44low/CD133 from MDA-MB-
468 cell line). Vitronectin and fibronectin were chosen based on previous
experiments in our laboratory that have demonstrated that MDA-MB-231
and MDA-MB-468 cells differentially express integrin receptors for
fibronectin and vitronectin, respectively ([37] and our unpublished data).
Cells were allowed to adhere for 5 hrs, after which the media were removed
and non-adhered cells were rinsed away. Adhered cells were fixed with 2%
gluteraldehyde and stained using Harris’ haematoxylin. Five high-powered
fields (HPF) (400) were counted for each well, and mean numbers of
adhered cells/field were calculated.
Cell migration and invasion assays
Transwell plates (6.5 mm, 8 
m pore size; Becton Dickinson; Franklin
Lakes, NJ, USA) were coated with 6 
g/well of gelatin (Sigma) (migra-
tion assay) or 10 
g/well of Matrigel (Becton Dickinson) (invasion assay)
as described previously [38, 39]. Control [0.01% bovine serum albumin
(BSA)] or chemoattractant (5% FBS) media were placed in the bottom
portion of each well. A total of 3.5  104 cells of each sorted population
(ALDHhiCD44CD24 and ALDHlowCD44low/CD24 from MDA-MB-231
cell line; ALDHhiCD44CD133 and ALDHlowCD44low/CD133 from
MDA-MB-468 cell line) were plated on top of the transwells. Cells were
allowed to migrate or invade for 24 hrs, after which the upper transwell
was removed, inverted, fixed with 1% gluteraldehyde and stained with
Harris’s haematoxylin. Non-migrated or non-invaded cells on the inner
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surface of the transwell were carefully removed using a cotton swab. Five
HPF were counted for each well, and mean numbers of migrated or
invaded cells/field were calculated.
In vivo animal experiments
All in vivo work was carried out using NOD/SCID-IL2 receptor null mice,
which permit increased tissue engraftment of human cells without rejection
due to reduced innate immunity (NOD mutation), complete T- and B-cell defi-
ciency (SCID mutation) and reduced natural killer (NK)-cell function (IL-2R
mutation) [40]. Animal procedures were conducted in accordance with the
recommendations of the Canadian Council on Animal Care, under a protocol
approved by the University of Western Ontario Council on Animal Care.
Following cell sorting, sorted populations (ALDHhiCD44CD24 and
ALDHlowCD44low/CD24 from MDA-MB-231 cell line; ALDHhiCD44CD133
and ALDHlowCD44low/CD133 from MDA-MB-468 cell line) were resus-
pended in sterile Hank’s buffered salt solution (MDA-MB-231) or PBS
(MDA-MB-468) at 5  106 cells/ml. Using established models of experi-
mental metastasis (tail vein injection) or spontaneous metastasis (mam-
mary fat pad injection) [33], 100 
l (5  105 cells) of each sorted cell 
population were injected into the lateral tail vein or right thoracic mammary
fat pad of 7–10-week-old female NOD/SCID-IL2R null mice (n 	 4
mice/group). Primary tumour growth was evaluated weekly by calliper
measurement in two perpendicular dimensions, and tumour volume was
estimated using the following formula: (volume 	 0.52  [width]2 
[length]) for approximating the volume (mm3) of an ellipsoid. Metastatic
growth in the lung and extrapulmonary organs was allowed to develop for
5–7 weeks (MDA-MB-231) or 12 weeks (MDA-MB-468), at which point the
mice were killed and assessed for metastatic burden. End-points and cell
numbers for injection were chosen based on preliminary experiments
using unsorted cell populations and NOD/SCID-IL2R null mice (data 
not shown).
Tissues and organs were examined superficially for evidence of gross
macroscopic metastases at necropsy. Tissues collected at necropsy were
then fixed in 10% neutral-buffered formalin, embedded in paraffin,
 sectioned randomly (4-
m sections; at least 100 
m apart; five sections/
tissue) and subjected to standard haematoxylin and eosin staining. Stained
slides were evaluated by light microscopy in a blinded fashion in order to
identify and characterize incidence and regions of micrometastatic involve-
ment. Metastatic tumour burden in the lung (tumour area/total organ area)
was determined quantitatively by manual outlining and analysis by ImageJ
software (NIH, Bethesda, MD, USA) as described previously [38].
Data analysis
Experiments analysing CSC marker phenotype and ALDH activity were per-
formed a minimum of three times. In vitro experiments with FACS-isolated
cells were performed twice (after four separate cell sorts) with at least
three biological replicates included within each experiment. In vivo studies
were carried out using multiple animals (n 	 4 per cell population) and
using cells obtained from five separate cell sorts. In all cases, quantitative
data were compiled from all experiments. Statistical analysis was per-
formed with GraphPad Prism 4.0 software© (San Diego, CA, USA) using
either t-test (for comparison between two groups) or ANOVA with Tukey
post-test (for comparison between more than two groups). Differences
between means were determined using the Student’s t-test when groups
passed both a normality test and an equal variance test. When this was not
the case, the Mann-Whitney rank sum test was used. Linear regression
was used to assess the relationship between primary tumour size and
metastatic burden in the lung. Unless otherwise noted, data are presented
as the mean  S.E.M. P-values of 0.05 were regarded as being statisti-
cally significant.
Results
Human breast cancer cell lines contain 
sub-populations of cells expressing prospective
CSC markers
Flow cytometry was used to assess the expression of prospective
CSC markers, including CD44/CD24 and CD133. Interestingly, the
most aggressive cell line (MDA-MB-435) had the highest propor-
tion of CD44CD24 cells (96.6  1.2%) (Fig. 1A), whereas the
least aggressive cell line (MCF-7) had the lowest proportion of
CD44CD24 cells (0.05  0.01%) (Fig. 1D). The moderately
metastatic MDA-MB-231 cell line contained 79.5  2.7%
CD44CD24 cells (Fig. 1B). In contrast, the weakly metastatic
MDA-MB-468 cell line contained very few cells (0.09  0.05%)
with a CD44CD24 phenotype; however, the majority of cells
(92.9  4.4%) did express both CD44 and CD24 (CD44CD24)
(Fig. 1C). Quantitative analysis demonstrated that the MDA-MB-
435 cell line contained significantly more cells with a
CD44CD24 phenotype than any of the other cell lines (P 0.01),
and that the MDA-MB-231 cell line had significantly more cells
with a CD44CD24 phenotype than either the MDA-MB-468 or
MCF-7 cell lines (P  0.01) (Fig. S1).
MDA-MB-435, MDA-MB-231 and MCF-7 cell lines did not
demonstrate expression of CD133 (Fig. 1A, B and D). However,
MDA-MB-468 cells did consistently express CD133 on their sur-
face, at a level significantly higher than the other cell lines (Fig. 1C).
Human breast cancer cell lines contain 
sub-populations of cells with enhanced 
ALDH activity
A complementary strategy for identifying cells with a
stem/progenitor phenotype involves measurement of ALDH activity
[24]. Human umbilical cord blood was assayed for ALDH activity
in order to provide a control for setting up the flow cytometry
 protocol and for confirming that the assay was working appropri-
ately (Fig. S2). The MDA-MB-435 cell line did not demonstrate any
significant increase in ALDH activity (Fig. 2A). Interestingly, both
the MDA-MB-231 and MDA-MB-468 cell lines showed two defini-
tive subpopulations of cells: one that had ALDH activity at the level
of the DEAB control, and one that had increased ALDH activity
(Fig. 2B and C). The MCF-7 cell line did not demonstrate any
increased ALDH activity (Fig. 2D).
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Fig. 1 Human breast cancer cell lines
contain sub-populations of cells express-
ing prospective CSC markers. (A–D) Flow
cytometry analysis of CD44/CD24 and
CD133. Antibodies used included an anti-
CD44 antibody (clone IM7) conjugated to
fluorescein isothiocyanate (FITC), an anti-
CD24 antibody (clone ML5) conjugated to
phycoerytherin (PE), an anti-CD133 anti-
body (clone AC133) conjugated to PE, or
appropriate FITC and PE-conjugated IgG
isotype controls. (A) MDA-MB-435 cells;
(B) MDA-MB-231 cells; (C) MDA-MB-468
cells and (D) MCF-7 cells. Left-hand pan-
els show representative dot plots of
CD44-FITC versus CD24-PE expression.
Cells which fell within the circled regions
were considered to express the phenotype
of interest (CD44CD24). Compiled
quantitative analysis of CD44CD24
phenotype expression from three sepa-
rate experiments is shown in Fig. S1. In
(C), cells which fell within the square
region were considered to express the
phenotype CD44CD24. Right-hand
panels show representative histograms of
CD133 expression (black profiles) relative
to the IgG isotype control (white profiles).
A minimum of 10,000 events were
 collected per sample.
J. Cell. Mol. Med. Vol 13, No 8B, 2009
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Strategy for isolation of stem-like human breast
cancer cells
MDA-MB-231 and MDA-MB-468 cell lines were chosen for fur-
ther characterization and functional analysis because they had the
most distinct subpopulations of cells with stem-like characteris-
tics (CSC marker expression, ALDH activity). Subsets of cells
were isolated from MDA-MB-231 and MDA-MB-468 cell lines by
FACS, using ALDH activity as the primary sort criteria and
CD44CD24 (MDA-MB-231 cells) or CD44CD133 (MDA-
MB-468 cells) phenotype as the secondary sort criteria. The
resulting cell subsets were designated as ALDHhiCD44CD24
(MDA-MB-231) or ALDHhiCD44CD133 (MDA-MB-468)
(‘stem-like’) and ALDHlowCD44low/CD24 (MDA-MB-231) or
ALDHlowCD44low/CD133 (MDA-MB-468) (non ‘stem-like’).
Examples of the cell sorting strategy are represented in Fig. 3
(MDA-MB-231) and Fig. 4 (MDA-MB-468). From this point forward
Fig. 2 Human breast cancer cell lines
contain sub-populations of cells with
enhanced ALDH activity. (A–D) Flow
cytometry analysis of ALDH activity. Cells
were assayed with ALDEFLUOR® assay
kit (StemCell Technologies) as per the
manufacturer’s guidelines. As a negative
control for all experiments, an aliquot of
ALDEFLUOR®-stained cells was immedi-
ately quenched with 1.5-mM diethy-
laminobenzaldehyde (DEAB), a specific
ALDH inhibitor. Cells were analysed using
the green fluorescence channel (FL1) on a
Beckman Coulter EPICS XL-MCL flow
cytometer. (A) MDA-MB-435 cells; (B)
MDA-MB-231 cells; (C) MDA-MB-468
cells and (D) MCF-7 cells. Left-hand pan-
els show representative dot plots of cells
treated with the ALDH-specific inhibitor
DEAB (negative controls). Right-hand
panels show representative dot plots of
ALDH activity. A minimum of 10,000
events were collected per sample. Cells
which fell within the circled regions were
considered to represent subpopulations
of cells with enhanced ALDH activity rela-
tive to the rest of the cell population. The
flow cytometry protocol was optimized
and validated using human umbilical cord
blood, which has a known population of
stem/progenitor cells with enhanced
ALDH activity (Fig. S2).
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Fig. 3 Strategy for isolation of stem-like human breast cancer cells from the MDA-MB-231 cell line. Fluorescence-activated cell sorting (FACS) was used
to isolate ALDHhiCD44 and ALDHlowCD44low/ human breast cancer cells for functional assays. MDA-MB-231 cells were concurrently labelled with 
7-AAD, fluorescent antibodies (CD44-APC  CD24-PE) and the ALDEFLUORTM assay kit. Cell subsets were isolated using a four-colour protocol on a
FACS Vantage/Diva cell sorter, including ALDHhiCD44CD24 and ALDHlowCD44low/CD24 subsets (A–C): Representative schematic of a sequentially
gated MDA-MB-231 cell line sort. (A) Cells were first selected for viability based on 7-AAD negativity (R1, left panel) and for singlets (R2, right panel).
(B) Cells were then selected based on light scatter (R3, left panel) and divided into ALDHlow (R4, bottom ~20% of parent population) and ALDHhi (R5,
top ~20% of parent population) based on ALDH activity (right panel). (C) Finally, ALDHlow cells were further selected based on a CD44low/CD24 phe-
notype (R6, bottom 10% of parent population, gated on R1  R2  R3  R4) (left panel), whereas ALDHhi cells were further selected based on expres-
sion of a CD44CD24 phenotype (R7, top ~10% of parent population, gated on R1  R2  R3  R5) (right panel ). The resulting cell subsets were
designated as ALDHhiCD44CD24 (R7, ‘stem-like’) and ALDHlowCD44low/CD24 (R6, non ‘stem-like’), and were collected for functional analysis of
differences in malignant and metastatic behaviour in vitro and in vivo.
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Fig. 4 Strategy for isolation of stem-like human breast cancer cells from the MDA-MB-468 cell line. Fluorescence-activated cell sorting (FACS) was used
to isolate ALDHhiCD44 and ALDHlowCD44low/ human breast cancer cells for functional assays. MDA-MB-468 cells were concurrently labelled with 
7-AAD, fluorescent antibodies (CD44-APC  CD133-PE) and the ALDEFLUORTM assay kit. Cell subsets were isolated using a four-colour protocol on a
FACS Vantage/Diva cell sorter, including ALDHhiCD44CD133 and ALDHlowCD44low/CD133 subsets (A–C): Representative schematic of a sequen-
tially gated MDA-MB-468 cell line sort. (A) Cells were first selected for viability based on 7-AAD negativity (R1, left panel) and for singlets (R2, right
panel ). (B) Cells were then selected based on light scatter (R3, left panel ) and divided into ALDHlow (R4, bottom ~20% of parent population) and ALDHhi
(R5, top ~20% of parent population) based on ALDH activity (right panel ). (C) Finally, ALDHlow cells were further selected based on a
CD44low/CD133low/ phenotype (R6, bottom 10% of parent population, gated on R1  R2  R3  R4) (left panel ), whereas ALDHhi cells were fur-
ther selected based on expression of a CD44CD133 phenotype (R7, top ~10% of parent population, gated on R1  R2  R3  R5) (right panel ).
The resulting cell subsets were designated as ALDHhiCD44CD133 (R7, ‘stem-like’) and ALDHlowCD44low/CD133 (R6, non ‘stem-like’), and were
collected for functional analysis of differences in malignant and metastatic behaviour in vitro and in vivo.
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in the study, the non-’stem-like’ cells from both cell lines will be
collectively referred to as respective ALDHlowCD44low/ subsets.
ALDHhiCD44CD24 and ALDHhiCD44CD133
breast cancer cells demonstrate enhanced cell
growth and colony formation in vitro
Differences in cell growth characteristics in vitro between sorted
subpopulations for both cell lines were assessed (Fig. 5).
ALDHhiCD44CD24 (MDA-MB-231) and ALDHhiCD44CD133
(MDA-MB-468) cells demonstrated increased growth in normal
culture relative to respective ALDHlowCD44low/ cell subsets. Lag
times (time to reach exponential growth phase) were also
observed to be shorter for ALDHhiCD44CD24 (MDA-MB-231 	
1 day) and ALDHhiCD44CD133 (MDA-MB-468 	 2 days) cells
versus respective ALDHlowCD44low/ cell subsets (7 days for both
cell lines) (Fig. 5A). Differences in colony-forming ability and
anchorage-independent growth between sorted subpopulations
were assessed using a soft agar assay (Fig. 5B and C). Both
ALDHhiCD44CD24 (MDA-MB-231) and ALDHhiCD44CD133
(MDA-MB-468) cell subsets formed significantly more colonies 
(P 0.001) (Fig. 5B) and larger colonies (P 0.05) (Fig. 5C) than
respective ALDHlowCD44low/– cell subsets.
ALDHhiCD44CD24 and ALDHhiCD44CD133
breast cancer cells demonstrate enhanced 
adhesion, migration and invasion in vitro
In vitro assays were used to compare sorted subpopulations
from the perspective of differences in cell adhesion, migration
and invasion (Fig. 6). ALDHhiCD44CD24 (MDA-MB-231) and
ALDHhiCD44CD133 (MDA-MB-468) cells were observed to 
be significantly more adherent to fibronectin (MDA-MB-231) or
vitronectin (MDA-MB-468) (Fig. 6A), significantly more migra-
tory towards serum (Fig. 6B) and significantly more invasive
through Matrigel (Fig. 6C) than respective ALDHlowCD44low/– cell
subsets (P  0.001).
ALDHhiCD44CD24 and ALDHhiCD44CD133
breast cancer cells demonstrate enhanced
tumorigenicity and metastasis in vivo
Standard experimental or spontaneous metastasis assays were
used to compare the ability of sorted subpopulations to establish
themselves and grow in vivo following cell injection into the tail
vein (Fig. 7) or mammary fat pad (Fig. 8) of NOD/SCID-IL2R null
mice. Following tail vein injection, metastatic tumour burden in the
lung (percentage of lung occupied by tumour) was significantly
higher in mice injected with ALDHhiCD44CD24 (MDA-MB-231)
or ALDHhiCD44CD133 (MDA-MB-468) cells versus respective
ALDHlowCD44low/ cell subsets (Fig. 7A and B) (P  0.05).
Analysis of incidence of metastases (percentage of mice demon-
strating metastatic growth) in the lung and extrapulmonary organs
revealed that, although all subpopulations of cells were able to
establish themselves in the lung (Fig. 7C), only ALDHhiCD44
CD24 (MDA-MB-231) and ALDHhiCD44CD133 (MDA-MB-
468) cells were able to maintain that growth into larger metastases
(Fig. 7A and B). Furthermore, metastases in extrapulmonary
organs such as the pancreas, liver, spleen and/or kidney were only
observed in mice injected with ALDHhiCD44CD24 (MDA-
MB-231) or ALDHhiCD44CD133 (MDA-MB-468) cells, and not
in mice injected with ALDHlowCD44low/ cell subsets (Fig. 7C).
In order to compare tumorigenicity and metastatic ability in a
more clinically relevant model system, we next used a sponta-
neous model of metastasis involving orthotopic injection of breast
cancer cells into the mammary fat pad. We observed that
ALDHhiCD44CD24 (MDA-MB-231) and ALDHhiCD44CD133
(MDA-MB-468) cells demonstrated enhanced primary tumour
growth relative to respective ALDHlowCD44low/ cell subsets
(Fig. 8A). Spontaneous metastatic tumour burden in the lung was
significantly higher in mice injected with ALDHhiCD44CD24
(MDA-MB-231) and ALDHhiCD44CD133 (MDA-MB-468) 
cells versus respective ALDHlowCD44low/ cell subsets (Fig. 8B)
(P  0.05). Interestingly, we did not observe a significant correla-
tion between primary tumour size and metastatic burden in the
lungs of individual mice, either in the ‘stem-like’ populations
(ALDHhiCD44CD24 and ALDHhiCD44CD133) (R2 	 0.365)
or in the respective ALDHlowCD44low/ populations (R2 	 0.530).
Similar to the observations following tail vein injection, although
all subpopulations of cells were able to establish themselves in the
lung (Fig. 8C), only ALDHhiCD44CD24 (MDA-MB-231) and
ALDHhiCD44CD133 (MDA-MB-468) had an enhanced capacity
to maintain that growth into larger metastases (Fig. 8B), and to
spontaneously metastasize to extrapulmonary organs such as the
pancreas and spleen (Fig. 8C).
Discussion
The majority of breast cancer deaths occur as a result of
metastatic disease rather than from the effects of the primary
tumour. The inefficiency of the metastatic process, the inher-
ently heterogeneous nature of solid tumours, and the influence
of the tumour microenvironment dictate that only a small sub-
set of cells can successfully navigate the metastatic cascade
and eventually re-initiate tumour growth to form life-threatening
metastases [1]. Although it has been speculated that this sub-
set of cells may be CSCs, most studies to date have focused on
the role of CSCs in primary tumour growth rather than on their
potential contribution to metastatic behaviour. Furthermore, the
challenges of obtaining large numbers of primary cells from
patient samples combined with the technical complexity of
studying metastasis of primary cells in vivo suggests that 
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Fig. 5 ALDHhiCD44CD24 and ALDHhiCD44CD133 breast cancer cells demonstrate enhanced cell growth and colony formation in vitro. Cells were
isolated by FACS as described in Figs 3 and 4 and subjected to in vitro assays for growth and colony formation. (A) Cell growth kinetics in normal
(anchorage-dependent) culture over time of ALDHhiCD44CD24 () versus ALDHlowCD44low/CD24 () cells isolated from the MDA-MB-231 cell
line (left panel ); and ALDHhiCD44CD133 () versus ALDHlowCD44low/ CD133 () cells isolated from the MDA-MB-468 cell line (right panel )
(5.0  104 cells/60 mm plate; n 	 3 plates/time-point). Data are presented as the mean  S.E.M. * 	 significantly different cell number than respec-
tive ALDHlowCD44low/ cell subsets (P  0.05). (B, C) Colony forming ability of ALDHhiCD44CD24 (MDA-MB-231) and ALDHhiCD44CD133
(MDA-MB-468) cells (black bars) versus respective ALDHlowCD44low/ cell subsets (white bars) isolated from MDA-MB-231 (left panels) or MDA-MB-
468 (right panels) cell lines. Cells (1.0  104 cells/60 mm plate, n 	 4 plates/cell population) were grown in soft agar (0.6%) for 4 weeks. Five high-
powered fields of view (100) were counted for each dish. (B) Mean number of colonies per plate and (C) Mean colony diameter (
m2). Data are pre-
sented as the mean  S.E.M.  	 significantly different colony number than respective ALDHlowCD44low/ cell subsets (P  0.001).  The value  	
significantly different colony size than respective ALDHlowCD44low/ cell subsets (P  0.05).
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Fig. 6 ALDHhiCD44CD24 and ALDHhiCD44CD133 breast cancer cells demonstrate enhanced adhesion, migration and invasion in vitro. (A) Cell
adhesion of ALDHhiCD44CD24 versus ALDHlowCD44low/CD24 cells isolated from the MDA-MB-231 cell line (left panel ); and ALDHhiCD44CD133
versus ALDHlowCD44low/ CD133 cells isolated from the MDA-MB-468 cell line (right panel ). Cells were isolated by FACS as described in Figs 3 and
4 and plated onto sterile 96-well non-tissue culture plates treated with either 10 
g/ml of fibronectin (MDA-MB-231 cells), 5 
g/ml of vitronectin (MDA-
MB-468 cells) (black bars) or PBS (negative control ) (white bars), using 1  104 cells/well in triplicate wells for each sorted cell population. Cells were
allowed to adhere for 5 hrs and adhered cells were quantified by manual counting of five high-powered fields (HPF) per well. Data are presented as the
mean  S.E.M. * 	 significantly different than respective population of ALDHlowCD44low/ cells adhered to vitronectin or fibronectin (P  0.001). (B)
Cell migration and (C) Cell invasion of ALDHhiCD44CD24 versus ALDHlowCD44low/CD24 cells isolated from the MDA-MB-231 cell line (left pan-
els); and ALDHhiCD44CD133 versus ALDHlowCD44low/ CD133 cells isolated from the MDA-MB-468 cell line (right panels). Transwells (8 
m) were
pre-coated with either gelatin (migration assays; 6 
g/well) or Matrigel (invasion assays; 10 
g/well) and FACS-isolated cells (3.5  104 cells/well; 
n 	 3 for each cell population) were allowed to migrate or invade for 24 hrs towards chemoattractant media (5% foetal bovine serum) (black bars) or
control media (0.01% bovine serum albumin) (white bars). Migrated or invaded cells were quantified by manual counting of five HPF per well. Data are
presented as the mean  S.E.M.  	 significantly different than respective population of ALDHlowCD44low/ cells migrating towards FBS (P  0.001).
 	 significantly different than respective population of ALDHlowCD44low/ cells invading through Matrigel towards FBS (P  0.001).
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Fig. 7 ALDHhiCD44CD24 and ALDHhiCD44CD133 breast cancer cells demonstrate enhanced metastatic growth in vivo following tail vein injection. Cells
were isolated by FACS as described in Figs 3 and 4 and injected into the lateral tail vein of female NOD/SCID-IL2R null mice using an established model of
experimental metastasis (5  105 cells/mouse; 4 mice/cell population). At 5 weeks (MDA-MB-231) or 12 weeks (MDA-MB-468) after injection, mice were killed
and assessed for metastatic burden in the lung and elsewhere. Tissue sections were subjected to haematoxylin and eosin staining (five random sec-
tions/tissue/mouse), and the incidence and extent of metastasis was determined in a blinded fashion. (A and B) Quantitative analysis of tumour burden (mean%
of lung occupied by tumour) (left panels) and representative haematoxylin and eosin stained lung sections (right panels) following tail vein injection of (A)
ALDHhiCD44CD24 versus ALDHlowCD44low/CD24 cells isolated from the MDA-MB-231 cell line; and (B) ALDHhiCD44CD133 versus
ALDHlowCD44low/CD133 cells isolated from the MDA-MB-468 cell line. Arrowheads on haematoxylin and eosin images indicate regions of tumour within the
lung. Data are presented as the mean  S.E.M. * 	 significantly different than respective ALDHlowCD44low/ subsets (P  0.05). (C) Incidence of metastatic
growth in lung and extrapulmonary tissues following tail vein injection of ALDHhiCD44CD24 versus ALDHlowCD44low/CD24 cells isolated from the MDA-
MB-231 cell line (left panels); and ALDHhiCD44CD133 versus ALDHlowCD44low/CD133 cells isolated from the MDA-MB-468 cell line (right panels).
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Fig. 8 ALDHhiCD44CD24 and ALDHhiCD44CD133 breast cancer cells demonstrate enhanced tumorigenicity and metastatic growth in vivo follow-
ing mammary fat pad injection. Cells were isolated by FACS as described in Figs 3 and 4 and injected into the right thoracic mammary fat pad of female
NOD/SCID-IL2R null mice using an established model of spontaneous metastasis (5  105 cells/mouse; 4 mice/cell population). At 7 weeks (MDA-
MB-231) or 12 weeks (MDA-MB-468) after injection, mice were killed and assessed for metastatic burden in the lung and elsewhere. Tissue sections
were subjected to haematoxylin and eosin staining (five random sections/tissue/mouse), and the incidence and extent of metastasis was determined 
in a blinded fashion. (A) Primary tumour growth kinetics following mammary fat pad injection of ALDHhiCD44CD24 () versus
ALDHlowCD44low/CD24 () cells isolated from the MDA-MB-231 cell line (left panel ); and ALDHhiCD44CD133 () versus ALDHlowCD44low/
CD133 () cells isolated from the MDA-MB-468 cell line (right panel). Data are presented as the mean  S.E.M. * 	 significantly different tumour
size than respective ALDHlowCD44low/ subsets at the same time-point (P  0.05). (B) Quantitative analysis of spontaneous lung metastasis tumour 
burden (mean% of lung occupied by tumour) following mammary fat pad injection of ALDHhiCD44CD24 versus ALDHlowCD44low/CD24 cells iso-
lated from the MDA-MB-231 cell line (left panel ); and ALDHhiCD44CD133 versus ALDHlowCD44low/ CD133 cells isolated from the MDA-MB-468
cell line (right panel ). Data are presented as the mean  S.E.M.  	 significantly different than respective ALDHlowCD44low/ subsets (P  0.05). (C)
Incidence of spontaneous metastatic growth in lung and extrapulmonary tissues following mammary fat pad injection of ALDHhiCD44CD24 versus
ALDHlowCD44low/CD24 cells isolated from the MDA-MB-231 cell line (left panel ); and ALDHhiCD44CD133 versus ALDHlowCD44low/ CD133 cells
isolated from the MDA-MB-468 cell line (right panel ).
J. Cell. Mol. Med. Vol 13, No 8B, 2009
2249© 2008 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
suitable alternative model systems need to be developed and
validated in order to gain a greater insight into the role of stem-
like cells in metastasis.
In the present study, we demonstrated that commonly studied
human breast cancer cell lines contain subpopulations of stem-like
cells based on both putative CSC marker expression (CD44/CD24
and CD133), and functional stem cell properties (enhanced ALDH
activity). Furthermore, the ‘stem-like’ cell content of the cell lines
seemed to be associated with their aggressiveness (i.e. the more
aggressive/metastatic the cell line, the greater the CD44 and/or
ALDHhi cell content). Our novel findings also demonstrated that
ALDHhiCD44CD24 (MDA-MB-231) and ALDHhiCD44CD133
(MDA-MB-468) cells isolated from human breast cancer cell lines
display significantly enhanced malignant/metastatic behaviour
compared to respective ALDHlowCD44low/ subsets, including
increased in vitro growth and colony forming ability in an anchor-
age-independent environment and increased in vitro adhesion,
migration and invasion. Moreover, when the different cell popula-
tions were isolated and injected into the tail vein or mammary fat
pad of NOD/SCID-IL2R null mice, the ALDHhiCD44CD24
(MDA-MB-231) and ALDHhiCD44CD133 (MDA-MB-468) popula-
tions showed increased tumorigenicity, increased metastatic growth
in the lungs and extrapulmonary metastases, whereas the respec-
tive ALDHlowCD44low/ populations showed minimal metastatic
growth in vivo.
Our findings are supported by two recently published studies
that also demonstrate a potential link between stem-like cancer cells
and successful metastatic behaviour [8, 41]. During the course of
carrying out the present study, Yu et al. (2007) published findings
demonstrating that stem-like cells isolated from the SKBR3 human
breast cancer cell line based on their mammosphere forming ability
were more metastatic in vivo than unsorted parental SKBR3 cells
[41]. In pancreatic cancer, Hermann et al. (2007) identified a sub-
population of cells within a CD133 cell population that expressed
the chemokine receptor CXCR4 [8]. In concert with its chemokine
ligand SDF-1, CXCR4 has been shown to play a key role in both nor-
mal stem cell migration and homing, as well as cancer cell migra-
tion and metastasis [42]. When the CXCR4 pancreatic CSC sub-
population was eliminated in various highly metastatic pancreatic
cancer cell lines, the cells could still efficiently form primary
tumours but were no longer able to metastasize [8]. This suggests
that the CSC population, at least in pancreatic cancer, is responsible
for metastasis, but only because of a small subgroup of CD133
CXCR4 CSCs. Interestingly, both MDA-MB-231 and MDA-MB-468
cell lines demonstrate moderate and uniform expression of CXCR4
(Fig. S3), suggesting that CXCR4 may also be important for metas-
tasis of stem-like cells in breast cancer.
Conventionally, CSC populations have been isolated from solid
human tumours based on cell surface expression of markers such
as CD133 and CD44 [6–11]. CD133 is a marker expressed by
many types of normal stem cells, including neural and
haematopoietic stem cells [9, 11], and has been shown to play a
role in stem cell migration and asymmetric division [43, 44]. CD44
is a cell surface receptor for hyaluronic acid, and is involved in cell
adhesion, migration and metastasis of cancer cells [23]. From a
functional perspective, it is therefore not surprising that these
markers would select for highly aggressive tumour cells. However,
although defined cell surface markers have long been used to reli-
ably isolate normal stem cells of various lineages, the inherent
genetic instability of solid cancers suggests that it may be prob-
lematic to rely on cell surface marker expression alone to prospec-
tively identify and isolate CSCs [20–23]. Self-protection is a key
property of normal stem cells, and is of vital importance for pro-
tecting and maintaining the stem cell pool throughout the lifespan
of an organism. ALDH activity is important for this self-protection
through its role in retinoic acid signalling and oxidation of intracel-
lular aldehydes [24, 45], and thus provides a means of identifying
and isolating stem-like cancer cells based on a conserved
stem/progenitor cell function.
When we analysed ALDH activity in human breast cancer cell
lines, the pattern of ALDH activity in different cell lines often cor-
responded to their observed pattern of CSC marker expression.
For example, in the case of the moderately metastatic MDA-MB-
231 and weakly metastatic MDA-MB-468 cell lines (where sub-
populations were evident in the marker expression analysis), two
distinct subpopulations were also observed with respect to ALDH
activity. Similarly, non-metastatic MCF-7 cells did not contain a
detectable CD44CD24 or CD133 subpopulation and showed
minimal increase in ALDH activity. There is evidence to support
the idea that isolating CSC-like cells by both marker expression
and ALDH activity is most accurate. When Ginestier et al. (2007)
isolated stem-like cells from primary human breast tumours using
both ALDH activity and CD44CD24, the ALDHhiCD44CD24
population was more tumorigenic than populations identified by
either marker expression or ALDH activity alone. Interestingly, the
overlap between CSC marker expression (CD44CD24) and high
ALDH activity in primary tumours was observed to be quite small
(~1%) [32]. In the present study, we investigated two distinct sub-
populations of ‘stem-like’ cells; ALDHhiCD44CD24 cells iso-
lated from the moderately metastatic MDA-MB-231 cell line and
ALDHhiCD44CD133 cells isolated from the weakly metastatic
MDA-MB-468 cell line. Although both populations behaved in a
similar manner from the point of view of having significantly
enhanced malignant and metastatic ability relative to their respec-
tive ALDHlowCD44low/ subsets, the in vitro and in vivo differences
in growth-related functional behaviour of ALDHhiCD44CD133
and ALDHlowCD44low/CD133 subsets were more subtle than those
between ALDHhiCD44CD24 and ALDHlowCD44low/CD24
subsets. These may simply be cell-line specific differences, or
they may be related to the differential use of CD133 versus CD24
to refine the ALDH isolation procedure. This is supported by a
recent study by Shmelkov et al. (2008), which demonstrated that
CD133 may not be restricted to stem cells and that both CD133
and CD133 metastatic colon cancer cells can initiate tumours in
vivo [46]. This, combined with the findings of our study and those
of Ginestier et al. (2007) [32], suggests that there is heterogene-
ity even within the CSC population of breast tumours, and that
ALDHhiCD44 cells (and ALDHhiCD44CD24 cells in particular)
may represent the most aggressive and malignant population
within the CSC pool.
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When the in vitro proliferative capacity of ALDHhiCD44CD24
(MDA-MB-231) and ALDHhiCD44CD133 (MDA-MB-468) versus
ALDHlowCD44low/ populations was compared in this study, it was
observed that the ALDHhiCD44CD24 and ALDHhiCD44CD133
populations demonstrated enhanced growth. Similarly, in vivo
studies demonstrated that ALDHhiCD44CD24 and ALDHhiCD44
CD133 showed enhanced primary tumour growth in the mam-
mary fat pad relative to respective ALDHlowCD44low/–populations.
Interestingly, although all cell subsets could establish themselves
in the lung as very small micrometastases, again only the
ALDHhiCD44CD24 and ALDHhiCD44CD133 cells had a sig-
nificantly enhanced capacity for metastatic growth resulting in
increased tumour burden in the lung and metastases to extrapul-
monary organs such as spleen and pancreas. In the context of
stem cell properties, these results were a bit surprising, because
it is well established that the proliferation rate of primitive stem
cells is lower than that of committed cells [43, 47–49]. However,
ALDH has been shown to identify rapidly dividing cells that rep-
resent a progenitor cell population in human umbilical cord
blood and bone marrow ([50] and our unpublished data), and
this may also be true in the context of breast cancer. The studies
described here suggest that both ALDHhiCD44CD24 and
ALDHhiCD44CD133 breast cancer cells may in fact demon-
strate a more proliferative progenitor-like phenotype (rather than a
quiescent stem cell phenotype), although further studies are
required to investigate this idea in more detail.
In summary, the novel findings presented here indicate that
ALDHhiCD44CD24 and ALDHhiCD44CD133 stem-like cancer
cells isolated from MDA-MB-231 and MDA-MB-468 human breast
cancer cell lines demonstrate enhanced malignant/metastatic
behaviour in vitro and in vivo, and suggest that breast cancer cell
lines may provide a suitable model system for starting to investigate
the role of stem-like cells in metastasis. Furthermore, our study rep-
resents the first report that selection and isolation of stem-like
breast cancer cells on the basis of ALDH activity can enhance for
functional cell properties that contribute to metastasis, including in
vitro adhesion, migration and invasion, and in vivo growth in pri-
mary and secondary organ sites. Further elucidation of the mecha-
nisms by which ALDHhiCD44CD24 and ALDHhiCD44CD133
populations successfully metastasize and the translation of this
knowledge into the clinic could have potentially important implica-
tions for the management and treatment of breast cancer.
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Supporting Information
Fig. S1 Compiled quantitative analysis of CD44CD24 surface
marker expression in human breast cancer cell lines. Human
breast cancer cells (MDA-MB-435, MDA-MB-231, MDA-MB-468,
MCF-7) were incubated with an anti-CD44 antibody (clone IM7)
conjugated to fluorescein isothiocyanate (FITC) and an anti-CD24
antibody (clone ML5) conjugated to phycoerytherin (PE), or
appropriate FITC and PE-conjugated IgG isotype controls.
Representative dot plots from the flow cytometry analysis can be
observed in Fig. 1. The percentage of cells with a CD44CD24
phenotype was used to assess CD44/CD24 cell surface expression
in each cell line. Data are presented as the mean  S.E.M. * 	
significantly larger CD44CD24 population relative to all other
cell lines (P  0.01).  	 significantly larger CD44CD24 pop-
ulation relative to MDA-MB-468 and MCF-7 cell lines (P  0.01).
Fig. S2 Optimization and validation of the ALDEFLUOR® assay kit
and flow cytometry protocol using human umbilical cord blood.
Cord blood was assayed with ALDEFLUOR® assay kit (StemCell
Technologies) as per the manufacturer’s guidelines. As a negative
control for all experiments, an aliquot of ALDEFLUOR®-stained cord
blood was immediately quenched with 1.5-mM diethylaminoben-
zaldehyde (DEAB), a specific ALDH inhibitor. Samples were
analysed using the green fluorescence channel (FL1) on a Beckman
Coulter EPICS XL-MCL flow cytometer, using the protocol set-up
and data acquisition template recommended by the  manufacturer.
(A) Representative dot plots of cord blood samples treated with the
ALDH-specific inhibitor DEAB (negative control). (B) Representative
dot plots of ALDH activity in cord blood. Cells which fell within the
circled regions represent subpopulations of cells with enhanced
ALDH activity relative to the rest of the cell population.
Fig. S3 MDA-MB-231 and MDA-MB-468 human breast cancer cell
lines express CXCR4. (A–B) Representative flow cytometry his-
tograms of (A) MDA-MB-231 cells and (B) MDA-MB-468 cells.
Cells were incubated with an anti-CXCR4 antibody (clone 12G5)
conjugated to phycoerytherin (PE) (black profiles) or a PE-conju-
gated IgG isotype control (white profiles). A minimum of 10,000
events were collected per sample.
This material is available as part of the online article from:
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1582-4934.2008.
00455.x
(This link will take you to the article abstract).
Please note: Wiley-Blackwell Publishing are not responsible for
the content or functionality of any supporting materials supplied
by the authors. Any queries (other than missing material) should
be directed to the corresponding author for the article.
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